CN107188900B - α7烟碱型乙酰胆碱受体的配体化合物及其应用 - Google Patents

α7烟碱型乙酰胆碱受体的配体化合物及其应用 Download PDF

Info

Publication number
CN107188900B
CN107188900B CN201710395513.0A CN201710395513A CN107188900B CN 107188900 B CN107188900 B CN 107188900B CN 201710395513 A CN201710395513 A CN 201710395513A CN 107188900 B CN107188900 B CN 107188900B
Authority
CN
China
Prior art keywords
compound
alpha
solution
added
nicotinic acetylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710395513.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107188900A (zh
Inventor
张华北
王欢
方煜
刘建萍
王淑霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Normal University
Original Assignee
Beijing Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201710395513.0A priority Critical patent/CN107188900B/zh
Application filed by Beijing Normal University filed Critical Beijing Normal University
Priority to RU2019140828A priority patent/RU2756604C2/ru
Priority to AU2017416647A priority patent/AU2017416647B2/en
Priority to US16/617,851 priority patent/US20200147243A1/en
Priority to JP2019565232A priority patent/JP6912602B2/ja
Priority to EP17911514.2A priority patent/EP3632918B1/de
Priority to PCT/CN2017/087339 priority patent/WO2018218696A1/zh
Priority to KR1020197038361A priority patent/KR102356040B1/ko
Publication of CN107188900A publication Critical patent/CN107188900A/zh
Application granted granted Critical
Publication of CN107188900B publication Critical patent/CN107188900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710395513.0A 2017-05-27 2017-05-27 α7烟碱型乙酰胆碱受体的配体化合物及其应用 Active CN107188900B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201710395513.0A CN107188900B (zh) 2017-05-27 2017-05-27 α7烟碱型乙酰胆碱受体的配体化合物及其应用
AU2017416647A AU2017416647B2 (en) 2017-05-27 2017-06-06 Ligand compound of α7 nicotinic acetylcholine receptor and application thereof
US16/617,851 US20200147243A1 (en) 2017-05-27 2017-06-06 Ligand compound of alpha7 nicotinic acetylcholine receptor and application thereof
JP2019565232A JP6912602B2 (ja) 2017-05-27 2017-06-06 α７ニコチン性アセチルコリン受容体のリガンド化合物及びその応用
RU2019140828A RU2756604C2 (ru) 2017-05-27 2017-06-06 ЛИГАНДНОЕ СОЕДИНЕНИЕ α7-НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ЕГО ПРИМЕНЕНИЕ
EP17911514.2A EP3632918B1 (de) 2017-05-27 2017-06-06 Ligandenverbindung von 7-nikotinischem acetylcholinrezeptor und anwendung davon
PCT/CN2017/087339 WO2018218696A1 (zh) 2017-05-27 2017-06-06 α7烟碱型乙酰胆碱受体的配体化合物及其应用
KR1020197038361A KR102356040B1 (ko) 2017-05-27 2017-06-06 α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710395513.0A CN107188900B (zh) 2017-05-27 2017-05-27 α7烟碱型乙酰胆碱受体的配体化合物及其应用

Publications (2)

Publication Number Publication Date
CN107188900A CN107188900A (zh) 2017-09-22
CN107188900B true CN107188900B (zh) 2019-09-06

Family

ID=59876106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710395513.0A Active CN107188900B (zh) 2017-05-27 2017-05-27 α7烟碱型乙酰胆碱受体的配体化合物及其应用

Country Status (8)

Country Link
US (1) US20200147243A1 (de)
EP (1) EP3632918B1 (de)
JP (1) JP6912602B2 (de)
KR (1) KR102356040B1 (de)
CN (1) CN107188900B (de)
AU (1) AU2017416647B2 (de)
RU (1) RU2756604C2 (de)
WO (1) WO2018218696A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676007B (zh) * 2018-06-22 2020-06-26 厦门大学 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用
CN109988173A (zh) * 2019-04-03 2019-07-09 北京师范大学 芴酮类α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2022255915A1 (en) * 2021-06-01 2022-12-08 Agneta Nordberg Pet radiotracers
CN113387867B (zh) * 2021-07-15 2023-03-14 南华大学 一种氨基甲酸酯类邻氨基苯甲酸色胺衍生物及其制备与应用
CN114804990B (zh) * 2022-04-18 2023-07-28 北京师范大学 一种季铵盐类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234031A1 (en) * 2004-02-04 2005-10-20 Schrimpf Michael R Amino-substituted tricyclic derivatives and methods of use
CN104262348A (zh) * 2014-08-15 2015-01-07 北京师范大学 一种α7烟碱型乙酰胆碱受体配体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006051413A1 (en) * 2004-11-15 2006-05-18 Pfizer Inc. Azabenoxazoles for the treatment of cns disorders
EP1814888A1 (de) * 2004-11-15 2007-08-08 Pfizer Products Incorporated Azabenzoxazole zur behandlung von erkrankungen des zentralen nervensystems
JP2008519820A (ja) * 2004-11-15 2008-06-12 ファイザー・プロダクツ・インク Ｃｎｓ障害の治療のためのアザベンゾオキサゾール
WO2007017750A1 (en) * 2005-08-08 2007-02-15 Pfizer Products Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
CN101370809A (zh) * 2006-02-14 2009-02-18 神经研究公司 新颖的二氮杂双环烷烃衍生物和它们的医药用途
EA034964B1 (ru) * 2011-10-20 2020-04-13 Новартис Аг Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
US20160235869A1 (en) * 2015-02-13 2016-08-18 The Johns Hopkins University DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234031A1 (en) * 2004-02-04 2005-10-20 Schrimpf Michael R Amino-substituted tricyclic derivatives and methods of use
CN104262348A (zh) * 2014-08-15 2015-01-07 北京师范大学 一种α7烟碱型乙酰胆碱受体配体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of 4-(5-Methyloxazolo [4, 5–b]pyridin-2-yl)- 1,4-diazabicyclo [3.2. 2]nonane (CP-810,123),a Novel r7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia;Christopher J. O’Donnell等;《J. Med. Chem.》;20091231;第53卷(第3期);全文，特别是摘要、表1-4
SAR of a7 nicotinic receptor agonists derived from tilorone: Exploration of a novel nicotinic pharmacophore;Michael R. Schrimpf等;《Bioorganic & Medicinal Chemistry Letters》;20120108;第22卷(第4期);全文，尤其是表1-3，摘要，前言

Also Published As

Publication number Publication date
CN107188900A (zh) 2017-09-22
RU2756604C2 (ru) 2021-10-04
JP2020523292A (ja) 2020-08-06
KR20200013702A (ko) 2020-02-07
US20200147243A1 (en) 2020-05-14
WO2018218696A1 (zh) 2018-12-06
EP3632918C0 (de) 2023-12-20
JP6912602B2 (ja) 2021-08-04
RU2019140828A3 (de) 2021-06-11
AU2017416647B2 (en) 2020-10-15
EP3632918A1 (de) 2020-04-08
EP3632918A4 (de) 2020-07-29
RU2019140828A (ru) 2021-06-11
EP3632918B1 (de) 2023-12-20
KR102356040B1 (ko) 2022-01-26
AU2017416647A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CN107188900B (zh) α7烟碱型乙酰胆碱受体的配体化合物及其应用
CN104470921B (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN105085474B (zh) 鲁顿酪氨酸激酶抑制剂
EA019252B1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
CN109475556A (zh) 用于治疗外周疾病的pde9抑制剂
CN110234638A (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
CN106414473A (zh) 多烯大环内酯衍生物
CN106349233A (zh) 3,4‑二苯基‑4h‑1,2,4‑三唑衍生物及其制备方法和应用
WO2020200283A1 (zh) 芴酮类α7烟碱型乙酰胆碱受体的配体化合物及其应用
TW202144369A (zh) 海鞘素類衍生物及其製備方法與醫藥用途
CN107501270B (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN110461369A (zh) 灵长类生物的脑内ampa受体的成像方法、程序、诊断药、伴随诊断药、医药、筛选方法、输入终端、服务器及系统
US11918662B2 (en) Heterocyclic compounds and imaging agents for imaging huntingtin protein
WO2022253335A1 (zh) 含磺酰基的芳基类化合物及其应用
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN108047145A (zh) 与Tau蛋白具有亲和力的2-芳基喹喔啉类化合物及其制备方法与应用
AU2020386151B2 (en) Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
CN102659796B (zh) 氟-18标记的螺环哌啶类sigma-1受体化合物及制备方法和应用
CN102548586A (zh) 羟基化的造影增强剂及其中间体
KR101307671B1 (ko) 글리신 1 운반체의 방사성표지된 억제제
Kumar et al. Synthesis and in vivo evaluation of [O-methyl-11C](2R, 4R)-4-hydroxy-2-[2-[2-[2-(3-methoxy) phenyl] ethyl] phenoxy] ethyl-1-methylpyrrolidine as a 5-HT2A receptor PET ligand
WO2024052549A1 (en) New contrast agents for use in diagnostic imaging
CN108299287A (zh) 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN107567453A (zh) (吲唑‑4‑基)六氢吡咯并吡咯酮类及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant